Details

Last Funding Type

Non-Equity Assistant

Industries

Biotechnology,Clinical Trials,Health Diagnostics,Life Science,Pharmaceutical

Founded date

Jan 1, 2017

Number Of Employee

11 - 50

Operating Status

Active

At the junction of precision medicine and behavioral health, our vision is to reduce suicide, stigma, and suffering in silence. Our products and services include:

- PTS-ID is a genomics test that provides objective information to help clinicians confidently and quickly assess patients with cortisol dysregulation associated with PTSD. Results of the test can be combined with behavioral risk survey data to give clinicians a whole-picture view of the patient’s state, enabling earlier, more targeted PTSD treatment.
Polaris’ TruNorth Platform provides comprehensive utilization of integrated data sources that creates a complete picture of patient health and PTSD risk.

TruGen-1 is a 1003-gene panel that supports genomic research across a spectrum of neuropsychiatric conditions.

Endeavor Lab is a nimble high-complexity CLIA lab that offers a wide variety of genomic sequencing, analysis, and lab testing services, including next-generation sequencing, CLIA / CAP clinical genetic testing, and assay processing, ushering a more in-depth understanding of neuropsychiatric conditions, and enabling the development of - and access to - precision diagnostics.

PTSD diagnostics and pandemic era Covid-19 testing are in this company’s DNA, but Polaris is also well versed in immunology and virology, and fluent in leveraging the power of genomics and machine learning.